2 October 2009

Contents

Antiretrovirals

• Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions

PK and drug interactions

• Raltegravir trough levels reduced by etravirine may require use of TDM

• Lopinavir/r affects PK exposure of some antimalarial drugs

• Darunavir/r increases exposure to nevirapine

• Interaction between Ginkgo biloba and efavirenz

• Use of raltegravir in HIV-positive transplant recipients

Basic science and immunology

• Trends in Immunology: free access issue on immune senescence

• Low viral loads in elite controllers

• Immune surveillance below the radar: study offers explanation for acyclovir’s failure to reduce HIV risk

• Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption

BHIVA news

• Detention and removal of HIV-positive people in the UK

Correspondence

• Letter: comment on swine flu algorithm

On the web

• 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

• Access to HCV treatment in Eastern Europe

• Guide to HIV and hepatitis B coinfection

• TAG pipeline report

• New TB website and resource

• HIV and the kidneys

• Video news: online resource